Review of clinical and laboratory experiences with molindone hydrochloride.
The literature concerning the pharmacokinetics, pharmacodynamics, receptor physiology, and clinical use of molindone is reviewed. Unanswered questions about the drug are addressed. Although molindone is reputed to have a short half-life (1.5 hours), clinical observations report a prolonged effect from a once-daily dose. Early in treatment, some patients show intolerance due to akathisia or extrapyramidal symptoms. This may be withdrawal dyskinesia due to discontinuation of another drug or an early adverse effect of molindone. Different effects on dopamine receptors have been described, but the significance of these properties for the development of tardive dyskinesia remains unclear.
D017109:Akathisia, Drug-Induced; D001480:Basal Ganglia Diseases / Q000139:chemically induced; D002986:Clinical Trials as Topic; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004409:Dyskinesia, Drug-Induced / Q000209:etiology; D006207:Half-Life; D006220:Haloperidol / Q000494:pharmacology; D006801:Humans; D007211:Indoles / Q000627:therapeutic use*; D001523:Mental Disorders / Q000188:drug therapy / Q000523:psychology; D008972:Molindone / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D011569:Psychiatric Status Rating Scales; D011954:Receptors, Dopamine / Q000187:drug effects; D012559:Schizophrenia / Q000188:drug therapy; D012565:Schizophrenic Psychology
D007211:Indoles; D011954:Receptors, Dopamine; D006220:Haloperidol; D008972:Molindone